Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

BioNTech SE

GlaxoSmithKline

Kadmon Hlds

Pfizer

Sanofi

Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.

3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health

Novo Nordisk A/S (NYSE: NVO) has agreed to pay $100 million to settle a 2017 investor suit that alleged the Company failed to disclose that it was under the same pricing pressures as its competitors. Related Content:   House Committee Questions Eli Lilly, Sanofi, Novo Nordisk On' Unacceptably High' Insulin Prices

Novo Nordisk Settles Insulin Pricing Lawsuit For $100M

ISSOIRE, France--(BUSINESS WIRE)--BIOCORP and NOVO NORDISK sign global partnership within diabetes on digital health

BIOCORP and NOVO NORDISK Sign Global Partnership Within Diabetes on Digital Health

HCA Healthcare

These two companies have outperformed the market in the past year, and they are likely to continue doing so.

2 Top Healthcare Stocks That Could Boost Your Portfolio in September (and Beyond)

Novo Nordisk AS's ( NVO , Financial) weight-loss drug is biopharma's most controversial blockbuster, according to a report from Evaluate Pharma. The highest and lowest forecasts for the Danish company's weight-loss drug, Saxenda, in 2026 equal 237% of consensus, according to sell-side analysts.

Analysts Differ Most About Potential for Novo's Weight-Loss Drug

The potential continuation in diabetes and obesity trends may provide positive long-term tailwinds for Novo. With health experts now urging Americans to get tested for diabetes at age 35 vs. 40, a potential increase in diagnoses could create a short-term catalyst.

Novo Nordisk: Dominance In The Diabetes Market

Eli Lilly

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

3 Big Drug/Biotech Outperformers Worth Keeping an Eye On (Revised)

House Energy & Commerce Committee leaders sent three letters to execs at Eli Lilly And Co (NYSE: LLY), Sanofi SA (NASDAQ: SNY), and Novo Nordisk A/S (NYSE: NVO), raising concerns that despite their supposed concern over the past two years with the price of insulin, the price still remains "unacceptably high." Committee chair Frank Pallone (D-NJ) and subcommittee chair Diana DeGette (D-CO) note in all three letters that the price of insulin in the U.S. is more than 10 times that of 33 other countries.

House Committee Questions Eli Lilly, Sanofi, Novo Nordisk On 'Unacceptably High' Insulin Prices

3 Big Drug/Biotech Outperformers Worth Keeping an Eye On

Accenture Plc

Visa

Protecting capital can be just as important as growing it.

3 Low-Risk Stocks for Conservative Investors

Bagsværd, Denmark, 11 August 202 1 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 10 August 2021

Bagsværd, Denmark, 10 August 202 1 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 9 August 2021

Bagsværd, Denmark, 9 August 202 1 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 5 August 2021

AbbVie

Merck

Novartis

Roche Holding AG

The Wall Street firm put big drugmakers' R&D programs through five different tests.

Here Are the Winners of Cowen's Big Pharma R&D Showdown

Novo Nordisk A/S (NVO) CEO Lars Jorgensen on Q2 2021 Results - Earnings Call Transcript

Novo Nordisk (NVO) delivers better-than-expected results for Q2. Sales are aided by growth in Diabetes and Obesity Care owing to elevated GLP-1 revenues.

Novo Nordisk's (NVO) Q2 Earnings and Sales Beat Estimates

Novo Nordisk A/S (NYSE:NVO) shares traded higher by 3.2% on Thursday morning after the insulin and diabetes care leader landed a major Wall Street upgrade. The Analyst: Bank of America analyst Sachin Jain upgraded Novo Nordisk from Neutral to Buy and raised his price target from $100.27 to $117.04.

BofA Upgrades Novo Nordisk, Says Wegovy Obesity Drug Launch 'Far Exceeded' Expectations

Novo Nordisk A/S (NYSE: NVO) Q2 sales increased 10% Y/Y (17% at CER) to DKK 33.04 billion. Sales in International Operations increased 13% (17% CER) at DKK18.2 billion, and sales in North America Operations increased by 7% (16% at CER) to DKK14.8 billion.

Novo Nordisk Shares Are Trading Higher As GLP-1 Treatments Boost Q2 Topline, Bottom-line

4 August 2021 - Financial report for the period 1 January 2021 to 30 June 2021

Novo Nordisk's net profit increased by 10% in the first six months of 2021

Prothena

The company is mainly known for its diabetes drugs but has some background in rare-disease drugs.

Why Is Novo Nordisk Buying a Rare-Disease Candidate?

Abbott Labs

Canaan Inc.

Check Point Software Technologies

Clorox

Canadian National Railway Company

Infosys

McCormick

NextEra Energy

NewMarket

Taiwan Semiconductor Manufacturing

Finding safe stocks with the potential to deliver outsized gains can be challenging, but this list of names is certainly a good place to start.

11 Safe Stocks for Superior Gains

Prothena (PRTA) announces an agreement to sell its clinical-stage antibody, PRX004, and the broader ATTR amyloidosis program for $1.2 billion to Novo Nordisk.

Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk

Novo Nordisk A/S (NYSE: NVO) will acquire Prothena Corporation plc's  (NASDAQ: PRTA) and clinical stage antibody PRX004 and broader ATTR amyloidosis program. PRX004 is a Phase 2 ready immunotherapy designed to deplete the amyloid deposits associated with the disease pathology of ATTR amyloidosis.

Novo Nordisk To Buy Prothena's ATTR Amyloidosis Program For Up To $1.2B

Shares of Prothena Corp. Plc were up 1.3% in premarket trading on Monday after the company announced a deal to sell its ATTR amyloidosis portfolio to Novo Nordisk in a $100 million deal that is worth up to $1.2 billion, based on milestones. ATTR amyloidosis is a rare disease that can cause a buildup of amyloid deposits in the body.

Prothena sells amyloidosis portfolio to Novo Nordisk for up to $1.2 billion

Danish drugmaker Novo Nordisk will acquire U.S. drug developer Prothena Corp's experimental heart therapy, PRX004, in a deal that could be worth up to $1.23 billion, the companies said on Monday.

Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 billion

News for Novo Nordisk Stock (NVO)